HIV and liver disease forum: conference proceedings.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

11 citing papers in PubMed.

1. Sustained long-term antiviral maintenance therapy in HCV/HIV-coinfected patients (SLAM-C).Journal of acquired immune deficiency syndromes (1999) · 2010
   Trial
2. HIV-1 infected peripheral blood mononuclear cells modulate the fibrogenic activity of hepatic stellate cells through secreted TGF-β and JNK signaling.PloS one · 2014
   Article
3. Acute and chronic T cell dynamics in the livers of simian immunodeficiency virus-infected macaques.Journal of virology · 2012
   Article
4. Liver transplantation trends in the HIV population.Digestive diseases and sciences · 2011
   Article
5. Mechanisms of alcohol-mediated hepatotoxicity in human-immunodeficiency-virus-infected patients.World journal of gastroenterology · 2011
   Review
6. HIV and HCV cooperatively promote hepatic fibrogenesis via induction of reactive oxygen species and NFkappaB.The Journal of biological chemistry · 2011
   Article
7. Hepatitis C patients' self-reported adherence to treatment with pegylated interferon and ribavirin.Alimentary pharmacology & therapeutics · 2008
   Article
8. Critical issues in the treatment of hepatitis C virus infection in methadone maintenance patients.Addiction (Abingdon, England) · 2008
   Review
9. Steatohepatitis: Risk factors and impact on disease severity in human immunodeficiency virus/hepatitis C virus coinfection.Hepatology (Baltimore, Md.) · 2008
   Article
10. Nonresponse to treatment for hepatitis C: current management strategies.Drugs · 2008
    Review
11. HIV and liver disease forum: conference proceedings.Hepatology (Baltimore, Md.) · 2007
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

3 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as